Paul E. Milligan

3.7k total citations · 2 hit papers
31 papers, 2.6k citations indexed

About

Paul E. Milligan is a scholar working on Cardiology and Cardiovascular Medicine, Pharmacology and Internal Medicine. According to data from OpenAlex, Paul E. Milligan has authored 31 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cardiology and Cardiovascular Medicine, 11 papers in Pharmacology and 7 papers in Internal Medicine. Recurrent topics in Paul E. Milligan's work include Pharmacogenetics and Drug Metabolism (11 papers), Atrial Fibrillation Management and Outcomes (10 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Paul E. Milligan is often cited by papers focused on Pharmacogenetics and Drug Metabolism (11 papers), Atrial Fibrillation Management and Outcomes (10 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Paul E. Milligan collaborates with scholars based in United States, Italy and Canada. Paul E. Milligan's co-authors include Brian F. Gage, Amy D. Waterman, Michael W. Rich, Yan Yan, Martha J. Radford, Robert Culverhouse, Charles Eby, Gerald A. Banet, Howard L. McLeod and Gloria R. Grice and has published in prestigious journals such as Blood, Diabetes and CHEST Journal.

In The Last Decade

Paul E. Milligan

30 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)

2006 733 citations Brian F. Gage, Yan Yan et al. American Heart Journal profile →
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

2008 595 citations Brian F. Gage, Charles Eby et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul E. Milligan United States	18	1.3k	1.2k	672	527	347	31	2.6k
Edith A. Nutescu United States	34	1.1k 0.9×	2.0k 1.6×	1.6k 2.4×	364 0.7×	338 1.0×	186	4.2k
Patrick Kesteven United Kingdom	19	1.9k 1.5×	944 0.8×	565 0.8×	772 1.5×	277 0.8×	51	3.4k
Charles S. Eby United States	22	903 0.7×	754 0.6×	628 0.9×	418 0.8×	120 0.3×	61	3.0k
Niclas Eriksson Sweden	23	2.1k 1.7×	1.2k 1.0×	439 0.7×	856 1.6×	326 0.9×	67	4.2k
Charles Eby United States	19	1.5k 1.2×	478 0.4×	191 0.3×	609 1.2×	250 0.7×	36	2.4k
Deepak Voora United States	27	1.5k 1.2×	802 0.6×	156 0.2×	609 1.2×	383 1.1×	102	3.6k
Larisa H. Cavallari United States	40	3.1k 2.4×	1.3k 1.0×	288 0.4×	861 1.6×	431 1.2×	198	5.3k
Henry I. Bussey United States	22	829 0.6×	3.4k 2.7×	2.2k 3.3×	297 0.6×	303 0.9×	59	5.3k
Humberto Vidaillet United States	28	600 0.5×	3.1k 2.5×	138 0.2×	282 0.5×	282 0.8×	78	4.8k
Joseph R. Walker United States	14	522 0.4×	2.5k 2.0×	572 0.9×	765 1.5×	101 0.3×	27	3.1k

Countries citing papers authored by Paul E. Milligan

Since Specialization

Citations

This map shows the geographic impact of Paul E. Milligan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul E. Milligan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul E. Milligan more than expected).

Fields of papers citing papers by Paul E. Milligan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul E. Milligan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul E. Milligan. The network helps show where Paul E. Milligan may publish in the future.

Co-authorship network of co-authors of Paul E. Milligan

This figure shows the co-authorship network connecting the top 25 collaborators of Paul E. Milligan. A scholar is included among the top collaborators of Paul E. Milligan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul E. Milligan. Paul E. Milligan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Giri, Tusar, et al.. (2019). Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis. International Journal for Vitamin and Nutrition Research. 90(1-2). 42–48. 10 indexed citations

Wang, Tzu‐Fei, Paul E. Milligan, Catherine Wong, et al.. (2013). Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thrombosis and Haemostasis. 111(1). 88–93. 99 indexed citations

Deych, Elena, Paul E. Milligan, Charles Eby, et al.. (2010). Gamma-glutamyl carboxylase and its influence on warfarin dose. Thrombosis and Haemostasis. 104(10). 750–754. 45 indexed citations

Voora, Deepak, Daniel C. Koboldt, Christopher R. King, et al.. (2010). A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans. Clinical Pharmacology & Therapeutics. 87(4). 445–451. 70 indexed citations

Harris, Jenine K., Paul M. Ridker, Paul E. Milligan, et al.. (2009). Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. Journal of Thrombosis and Haemostasis. 8(1). 95–100. 61 indexed citations

Lenzini, Petra, Gloria R. Grice, Paul E. Milligan, et al.. (2008). Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. Journal of Thrombosis and Haemostasis. 6(10). 1655–1662. 66 indexed citations

Grice, Gloria R., et al.. (2008). Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes. Journal of Thrombosis and Haemostasis. 6(9). 1445–1449. 15 indexed citations

Gage, Brian F., Charles Eby, JA Johnson, et al.. (2008). Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin. Clinical Pharmacology & Therapeutics. 84(3). 326–331. 595 indexed citations breakdown →

Garbutt, Jane, Paul E. Milligan, Candace D. McNaughton, et al.. (2008). Reducing Medication Prescribing Errors in a Teaching Hospital. The Joint Commission Journal on Quality and Patient Safety. 34(9). 528–536. 12 indexed citations

10.

Lenzini, Petra, Gloria R. Grice, Paul E. Milligan, et al.. (2007). Anticoagulation: Optimal Initial Dose Adjustment of Warfarin in Orthopedic Patients. Annals of Pharmacotherapy. 41(11). 1798–1804. 23 indexed citations

11.

Grice, Gloria R., Paul E. Milligan, Susan K. Gatchel, et al.. (2007). Optimal dose adjustment in orthopedic patients beginning warfarin therapy. Journal of Thrombosis and Thrombolysis. 25(1). 102–102. 1 indexed citations

12.

Gage, Brian F., Yan Yan, Paul E. Milligan, et al.. (2006). Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). American Heart Journal. 151(3). 713–719. 733 indexed citations breakdown →

13.

Gage, Brian F. & Paul E. Milligan. (2005). Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements. Thrombosis Research. 117(1-2). 55–59. 12 indexed citations

14.

Voora, Deepak, Charles Eby, Mark W. Linder, et al.. (2005). Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thrombosis and Haemostasis. 93(4). 700–705. 154 indexed citations

15.

Eby, Charles, et al.. (2003). Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thrombosis and Haemostasis. 91(1). 87–94. 249 indexed citations

16.

Banet, Gerald A., Amy D. Waterman, Paul E. Milligan, Susan K. Gatchel, & Brian F. Gage. (2003). Warfarin Dose Reduction vs Watchful Waiting for Mild Elevations in the International Normalized Ratio*. CHEST Journal. 123(2). 499–503. 25 indexed citations

17.

Beyth, Rebecca J., Paul E. Milligan, & Brian F. Gage. (2002). Risk factors for bleeding in patients taking coumarins.. PubMed. 1(1). 41–9. 31 indexed citations

18.

Milligan, Paul E., Gerald A. Banet, Amy D. Waterman, Susan K. Gatchel, & Brian F. Gage. (2002). Substitution of Generic Warfarin for Coumadin in an HMO Setting. Annals of Pharmacotherapy. 36(5). 764–768. 31 indexed citations

19.

Waterman, Amy D., Gerald A. Banet, Paul E. Milligan, et al.. (2001). Patient and physician satisfaction with a telephone-based anticoagulation service. Journal of General Internal Medicine. 16(7). 460–463. 42 indexed citations

20.

Waterman, Amy D., Paul E. Milligan, Gerald A. Banet, Susan K. Gatchel, & Brian F. Gage. (2001). Establishing and running an effective telephone-based anticoagulation service. Journal of Vascular Nursing. 19(4). 126–133. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact